Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The aim of the study was to assess risedronate's effect on bone mineral density in postmenopausal women with rheumatoid arthritis receiving glucocorticoids. We carried out a two center, 2 year, double-masked, placebo-controlled trial with a third year of nontreatment follow-up. We studied 120 women requiring long-term glucocorticoid therapy at > 2.5 mg/day prednisolone randomized to treatment with daily placebo; daily 2.5 mg risedronate; or cyclical 15 mg risedronate (2 out of 12 weeks). At 97 weeks, bone mineral density was maintained at the lumbar spine (+1.4%) and trochanter (+0.4%) in the daily 2.5 mg risedronate group, while significant bone loss occurred in the placebo group (-1.6%, p = 0.03; and 4.0%, p < 0.005, respectively). At the femoral neck, there was a nonsignificant bone loss in the daily 2.5 mg risedronate group (-1.0%) while in the placebo group bone mass decreased significantly (-3.6%, p < 0.001). The difference between placebo and daily 2.5 mg risedronate groups was significant at the lumbar spine (p = 0.009) and trochanter (p = 0.02) but did not reach statistical significance at the femoral neck. Although not significantly different from placebo at the lumbar spine, the overall effect of the cyclical regimen was similar to that of the daily 2.5 mg risedronate regimen. Treatment withdrawal led to bone loss in the risedronate groups that was significant at the lumbar spine. A similar number of patients experienced adverse events (including upper gastrointestinal events) across treatment groups and risedronate was generally well tolerated. Thus risedronate preserves bone mass in postmenopausal women with rheumatoid arthritis receiving glucocorticoids while patients receiving a placebo have significant bone loss.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Risedronate is also approved for treatment to increase bone mass in men with osteoporosis and for the prevention and treatment of osteoporosis in men and women who are either initiating or taking glucocorticoids [75].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [75]
Citations
Cites
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management
Lukert, B. P., & Raisz, L. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-5-352 · Cited by 1,066
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615 · cited 1×
“As inhibitors of bone resorption, bisphosphonates are becoming widely used in the management of postmenopausal osteoporosis [ 10 ].”
BackgroundSelf-citationPrevalence and incidence of vertebral deformities
Melton, L. J., Lane, A. W., Cooper, C., Eastell, R., O'Fallon, W. M., & Riggs, B. L. (1993) · Osteoporosis International · doi:10.1007/bf01623271 · Cited by 517
Self-citationPeel, N. F., Moore, D. J., Barrington, N. A., Bax, D. E., & Eastell, R. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.10.801 · Cited by 379
Self-citationA UK Consensus Group on management of glucocorticoid‐induced osteoporosis: an update
Eastell, R., Reid, D. M., Compston, J., Cooper, C., Fogelman, I., Francis, R. M., Hosking, D. J., Purdie, D. W., Ralston, S. H., Reeve, J., et al. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00408.x · Cited by 315 · cited 2×
“After low bone mass has developed, the use of other agents such as bisphosphonates has been recommended [ 4 ].”
BackgroundSelf-citationHAHN, T. J., HALSTEAD, L. R., & BARAN, D. T. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-1-111 · Cited by 308
Dykman, T. R., Gluck, O. S., Murphy, W. A., Hahn, T. J., & Hahn, B. H. (1985) · Arthritis & Rheumatism · doi:10.1002/art.1780280402 · Cited by 281
Glucocorticoid osteoporosis--mechanisms and management
Reid, I. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370209 · Cited by 278
Risk of vertebral fracture in women with rheumatoid arthritis.
Spector, T. D., Hall, G. M., McCloskey, E. V., & Kanis, J. A. (1993) · BMJ · doi:10.1136/bmj.306.6877.558 · Cited by 230
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
An overview and management of osteoporosis
Sözen, T., Özışık, L., & Çalık Başaran, N. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2016.048 · Cited by 2,262
“A drug holiday of up to 1 year after 7 years of therapy has been suggested (42).”
BackgroundThe clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
“Actonel® is approved to increase bone mass in men with osteoporosis and to prevent and treat osteoporosis in men and women who are either initiating or taking glucocorticoids [158, 159].”
BackgroundHodgson, S. F., Watts, N. B., Bilezikian, J. P., Clarke, B. L., Gray, T. K., Harris, D. W., Conrad Johnston, C., Kleerekoper, M., Lindsay, R., Luckey, M. M., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.6.544 · Cited by 605
Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J., Boonen, S., Borgström, F., Cooper, C., Diez Perez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335
“For the bisphosphonates, alendronate [77–81], etidronate [82–91], risedronate [92–96] and zoledronic acid [97], and for the osteoanabolic, teriparatide, there is good evidence from placebo-controlled or comparator studies of beneficial effects on spine and hip BMD [98, 99].”
BackgroundSelf-citationSuzuki, Y., Nawata, H., Soen, S., Fujiwara, S., Nakayama, H., Tanaka, I., Ozono, K., Sagawa, A., Takayanagi, R., Tanaka, H., et al. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0586-6 · Cited by 281
Osteoporosis in Men: A Review of an Underestimated Bone Condition
Rinonapoli, G., Ruggiero, C., Meccariello, L., Bisaccia, M., Ceccarini, P., & Caraffa, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042105 · Cited by 245
Bisphosphonates for the prevention and treatment of osteoporosis
Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 178
Glucocorticoids and bone: Local effects and systemic implications
Henneicke, H., Gasparini, S. J., Brennan-Speranza, T. C., Zhou, H., & Seibel, M. J. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.006 · Cited by 168
Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis
Kanis, J., Stevenson, M., McCloskey, E., Davis, S., & Lloyd-Jones, M. (2007) · Health Technology Assessment · doi:10.3310/hta11070 · Cited by 151
Reid, D. M., Adami, S., Devogelaer, J.-P., & Chines, A. A. (2001) · Calcified Tissue International · doi:10.1007/s00223-001-1060-8 · Cited by 160
Self-citationFederal clinical guidelines for diagnosis, treatment and prevention of osteoporosis
Belaya, Z. E., Belova, K. Y., Biryukova, E. V., Dedov, I. I., Dzeranova, L. K., Drapkina, O. M., Dreval', A. V., Dubovitskaya, Т. A., Dudinskaya, Е. N., Ershova, O. B., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12930 · Cited by 160
Hodgson, S. F., Nb, W., Bilezikian, J. P., Clarke, B. L., Gray, T. K., Johnston, C. C., Kleerekoper, M., Lindsay, R. S., Luckey, M. M., McClung, M. R., et al. (2001) · Endocrine Practice · Cited by 157
Devogelaer, J., Goemaere, S., Boonen, S., Body, J., Kaufman, J., Reginster, J., Rozenberg, S., & Boutsen, Y. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2032-z · Cited by 155
“In a preliminary study, 120 postmenopausal women with rheumatoid arthritis who required long-term (>6 months) treatment with oral GCs at an average daily dose of at least 2.5 mg prednisolone received either a placebo, 2.5 mg risedronate (RIS) daily or cyclical 15 mg RIS (15 mg RIS for 2 weeks followed by a placebo dai…”
BackgroundInfluentialSelf-citationOsteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Görtz, B., Schulz, A., Bergmeister, H., Kollias, G., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11150 · Cited by 150
Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
Cryer, B., & Bauer, D. C. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.10.1031 · Cited by 148
Estrogens in rheumatoid arthritis; the immune system and bone
Islander, U., Jochéms, C., Lagerquist, M. K., Forsblad‐d’Elia, H., & Carlsten, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.05.018 · Cited by 148
Bone targeted nano-drug and nano-delivery
Wu, Y., Sun, B., Tang, Y. K., Shen, A., Lin, Y., Zhao, X., Li, J., Monteiro, M. J., & Gu, W. (2024) · Bone Research · doi:10.1038/s41413-024-00356-2 · Cited by 148
“162 163 – 165 Among the BP family drugs, oral administration of Alendronate (ALN) and IV administration of Zoledronate (ZOL) are widely used for osteoporosis patients, while ZOL therapy showed a superior effect to increase bone mineral density compared to ALN.”
BackgroundSaag, K. G., Pannacciulli, N., Geusens, P., Adachi, J. D., Messina, O. D., Morales‐Torres, J., Emkey, R., Butler, P. W., Yin, X., & Lems, W. F. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40874 · Cited by 140
Amin, S., LaValley, M. P., Simms, R. W., & Felson, D. T. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.8.1512 · Cited by 127
“Of relevant trials excluded from our analyses because of their failure to meet our eligibility criteria, (including one recently published trial((91)) identified initially as an abstract and excluded because of insufficient results based on the abstract), their findings generally were similar to our estimates; therefo…”
ResultDisorders Associated With Acute Rapid and Severe Bone Loss
Epstein, S., Inzerillo, A. M., Caminis, J., & Zaidi, M. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2083 · Cited by 112
Macías, J. G., Gay, N. G., Alonso, C. G., Barquero, L. M. D. R., Torres, M. M., Delgado‐Rodríguez, M., Pérez-Edo, L., López, J. B. D., Gimeno, E. J., & Carranza, F. H. (2008) · Revista Clínica Española · doi:10.1016/s0014-2565(08)71780-6 · Cited by 111
Teriparatide in the management of osteoporosis
Riggs (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s241 · Cited by 93
“Both risedronate and alendronate have been shown to substantially decrease the risk of fractures in glucocorticoid-induced osteoporosis (GIO), and treatment with these agents has become standard of care (Saag et al 1998; Eastell et al 2000).”
Brumsen, C., Papapoulos, S. E., Lips, P. T. A. M., Geelhoed-Duijvestijn, P. H. L. M., Hamdy, N. A. T., Landman, J. O., McCloskey, E. V., Netelenbos, J. C., Pauwels, E. K. J., Roos, J. C., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1057 · Cited by 89
Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
de Nijs, R. N. J. (2008) · PubMed · Cited by 87
Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation
Goffin, E. J., Devogelaer, J., Lalaoui, A., Depresseux, G., Naeyer, P. D., Squifflet, J., Pirson, Y., & de Strihou, C. V. Y. (2002) · Transplant International · doi:10.1111/j.1432-2277.2002.tb00133.x · Cited by 78
Self-citationFeng, R., Li, F., Yuan, Z., Wang, D., Wang, F., Tan, B., Han, S., Li, T., Li, D., & Han, Y. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9533-8 · Cited by 73
Effects of bisphosphonates on osteoporosis: Focus on zoledronate
Oryan, A., & Sahvieh, S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118681 · Cited by 64
Devogelaer, J., Adler, R. A., Recknor, C. P., See, K., Warner, M. R., Wong, M., & Krohn, K. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090411 · Cited by 61
“Synthetic human PTH [hPTH (1-34)] was found to increase bone mass in postmenopausal women with GIO who were also taking hormone replacement12,13.”
BackgroundSelf-citationRegulation of bone destruction in rheumatoid arthritis through RANKL-RANK pathways
Tanaka, S. (2013) · World Journal of Orthopedics · doi:10.5312/wjo.v4.i1.1 · Cited by 60
Bitto, A., Burnett, B. P., Polito, F., Levy, R. M., Marini, H. R., Stefano, V. D., Irrera, N., Armbruster, M. A., Minutoli, L., Altavilla, D., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00100.x · Cited by 60
“…vitamin D in one of its many forms (cholecalciferol, calciferol, calcitriol, calcidiol, alfacalcidol), calcitonin, parathyroid hormone, fluoride, testosterone and anabolic steroids (Adachi et al., 1996; Ringe et al., 1999; Eastell et al., 2000; Boutsen et al., 2001; Crandall, 2002; Sambrook, 2007).”
BackgroundRisedronate: A Clinical Review
Crandall, C. J. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.353 · Cited by 58
Elbers, L. P. B., Raterman, H. G., & Lems, W. F. (2021) · Drugs · doi:10.1007/s40265-021-01587-x · Cited by 56
“This might play a role, since earlier data suggest that bone loss is larger after cyclical treatment than after daily treatment (with risedronate) [29].”
BackgroundBisphosphonate therapy in rheumatoid arthritis
Breuil, V., & Euller‐Ziegler, L. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2005.10.019 · Cited by 55
Corticosteroid-Induced Osteoporosis: Detection and Management
Adachi, J. D., & Papaioannou, A. (2001) · Drug Safety · doi:10.2165/00002018-200124080-00005 · Cited by 55
Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management
McIlwain, H. H. (2003) · Preventive Medicine · doi:10.1016/s0091-7435(02)00019-1 · Cited by 53
Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Summey, B. T., & Yosipovitch, G. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.1.82 · Cited by 51
The delivery of evidence-based preventive care for older Americans with arthritis
Curtis, J. R., Arora, T., Narongroeknawin, P., Taylor, A. J., Bingham, C. O., Cush, J. J., Saag, K. G., Safford, M. M., & Delzell, E. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3086 · Cited by 50
Bitto, A., Polito, F., Burnett, B. P., Levy, R. M., Stefano, V. D., Armbruster, M. A., Marini, H. R., Minutoli, L., Altavilla, D., & Squadrito, F. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0552 · Cited by 50
“Proposed treatments include bisphosphonates, hormone replacement therapy, vitamin D (cholecalciferol or calciferol) and calcium, calcitriol, calcidiol, alfacalcidol, calcitonin, fluoride, testosterone and anabolic steroids (Adachi et al. 1996; Boutsen et al. 2001; Eastell et al. 2000; Ringe et al. 1999; Crandall 2002;…”
BackgroundCunningham, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050427 · Cited by 47
Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
Park, S. Y., Gong, H. S., Kim, K. M., Kim, D., Kim, H. Y., Jeon, C. H., Ju, J. H., Lee, S., Park, D. A., Sung, Y., et al. (2018) · Journal of Bone Metabolism · doi:10.11005/jbm.2018.25.4.195 · Cited by 46
“Alendronate and risedronate can be used as oral bisphosphonates, and the effects of alendronate [42-46,55,56] and risedronate [47-49,57-59] on the prevention and treatment of GIOP have been demonstrated through several studies.”
BackgroundGlucocorticoid-Induced Osteoporosis: Mechanisms and Therapeutic Approach
Devogelaer, J. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.09.001 · Cited by 45
Self-citationManagement of Bone Loss in Men With Prostate Cancer
Higano, C. S. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000097351.48848.1f · Cited by 44
Feng, Z., Zeng, S., Wang, Y., Zheng, Z., & Chen, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080890 · Cited by 43
“While Frediani et al [19] observed that clodronate can effectively reduce the incidence of vertebral fractures in patients with RA and psoriatic arthritis, Eastell et al [20] and Lems et al [21] reported that risedronate and alendronate had no effect on the prevention of vertebral fractures in rheumatic patients.”
BackgroundResultInfluentialPamidronate Therapy for Preventing Steroid-Induced Osteoporosis in Children with Nephropathy
Kim, S.-D., & Cho, B.-S. (2005) · Nephron Clinical Practice · doi:10.1159/000089664 · Cited by 43
Induction of osteogenesis by bone-targeted Notch activation
Xu, C., Dinh, V. V., Kruse, K., Jeong, H.-W., Watson, E. C., Adams, S., Berkenfeld, F., Stehling, M., Rasouli, S. J., Fan, R., et al. (2022) · eLife · doi:10.7554/elife.60183 · Cited by 42
Ettinger, B. B., Chidambaran, P., & Pressman, A. R. (2001) · PubMed · Cited by 42
TAWARA, D., Sakamoto, J., Murakami, H., Kawahara, N., Juhachi, O. D. A., & Tomita, K. (2009) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2009.03.001 · Cited by 40
Bone health in systemic lupus erythematosus
Panopalis, P., & Yazdany, J. (2009) · Current Rheumatology Reports · doi:10.1007/s11926-009-0024-2 · Cited by 39
Toukap, A. N., Depresseux, G., Devogelaer, J., & Houssiau, F. (2005) · Lupus · doi:10.1191/0961203305lu2149oa · Cited by 38
Self-citationBalooch, G., Yao, W., Ager, J. W., Balooch, M., Nalla, R. K., Porter, A. E., Ritchie, R. O., & Lane, N. E. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22976 · Cited by 37
“the lumbar spine increased by 1–3% during this treatment period (5,9,11,12).”
BackgroundWalsh, M. W., Jayne, D. R. W., MOIST, L. M., Tonelli, M. A., Pannu, N., & Manns, B. (2010) · Lupus · doi:10.1177/0961203309356292 · Cited by 37
Aurich‐Barrera, B., Wilton, L., Harris, S., & Shakir, S. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1986-1 · Cited by 35
“mass density and decreased vertebral fracture risk [17–21].”
BackgroundGlucocorticoid-induced osteoporosis
de Gregório, L. H., Lacativa, P. G. S., Melazzi, A. C. C., & Russo, L. A. T. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000400024 · Cited by 33
“Risedronate preserves bone mass in postmenopausal women with rheumatoid arthritis receiving glucocorticoids while patients receiving a placebo have significant bone loss (54).”
BackgroundMok, C. C., Tong, M. K. H., To, C. H., Siu, Y.-P., & M., K. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0505-y · Cited by 33
“Up to 21% of patients who received oral bisphosphonates such as risedronate and alendronate developed upper GI events such as esophagitis, esophageal ulcer, nausea, dyspepsia and gastritis in various controlled trials [12–17, 22, 23].”
BackgroundResultInfluentialTaşçıoğlu, F., Çolak, Ö., Armağan, O., Alataş, Ö., & Öner, C. (2005) · Rheumatology International · doi:10.1007/s00296-004-0496-3 · Cited by 33
“In several clinical trials conducted in RA patients with established osteoporosis, it has been shown that bisphosphonates such as etidronate [18, 19, 20], risedronate [ 21 ], and pamidronate [22 ]p roduced significant and progressive increases in bone mineral density (BMD) at the lumbar spine and the hip.”
BackgroundPrevention and treatment of glucocorticoid-induced osteoporosis in 2005
Orcel, P. (2005) · Joint Bone Spine · doi:10.1016/j.jbspin.2005.09.002 · Cited by 32
Bisphosphonates in bone diseases other than osteoporosis
Orcel, P., & Beaudreuil, J. (2002) · Joint Bone Spine · doi:10.1016/s1297-319x(01)00336-0 · Cited by 31
Glucocorticoids and the risk of osteoporosis
Caplan, L., & Saag, K. G. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802648194 · Cited by 30
Jochéms, C., Lagerquist, M. K., Håkansson, C. H., Ohlsson, C., & Carlsten, H. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03660.x · Cited by 29
Yates, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2179-3 · Cited by 26
Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis
Nuti, R. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.208 · Cited by 25
“5 mg/day, confirmed risedronate ability of preserving bone mineral density in patients in protracted corticosteroid treatment (39).”
BackgroundHenríquez, M. S., Díaz Curiel, M., Díez‐Pérez, A., Alonso, C. G., Macías, J. G., Farrerons, J., Rubio, J. F., Mellibovsky, L., Nogués, X., & Hernández, D. (2008) · Revista Clínica Española · doi:10.1157/13115006 · Cited by 25
Glüer, C.-C., Scholz-Ahrens, K. E., Helfenstein, A., Delling, G., Timm, W., Açil, Y., Barkmann, R., Hassenpflug, J., Stampa, B., Bauss, F., et al. (2006) · Bone · doi:10.1016/j.bone.2006.10.019 · Cited by 25
“For residronate, a cyclical regimen was equally effective for protecting against GC-induced BMD loss at the femur but was less efficacious at the spine when compared to daily administration [23].”
BackgroundAnimal Models in Osteoporosis Research
Kimmel, D. B. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50197-9 · Cited by 25
A summary of the Russian clinical guidelines on the diagnosis and treatment of osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Dedov, I. I., Drapkina, O. M., Fadeev, V. V., Golounina, O. O., Lesnyak, O. M., Mamedova, E., Mel'nichenko, G. A., Petraikin, A. V., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-022-06667-6 · Cited by 24
Liu, Z., Zhang, M., Shen, Z., Ke, J., Zhang, D., & Yin, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243851 · Cited by 24
Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation
Dombrecht, E. J., Tollenaere, C. B. D., Aerts, K., Cos, P., Schuerwegh, A. J., Bridts, C. H., Offel, J. F. V., Ebo, D. G., Stevens, W. J., & Clerck, L. S. D. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.07.075 · Cited by 24
Prevention of Glucocorticoid-induced Osteoporosis
Saag, K. G. (2004) · Southern Medical Journal · doi:10.1097/00007611-200406000-00008 · Cited by 24
Low dose glucocorticoids in early rheumatoid arthritis.
Strand, V., & Simon, L. S. (2003) · PubMed · Cited by 22
Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis
Park, S. Y., Gong, H. S., Kim, K. M., Kim, D., Kim, H. Y., Jeon, C. H., Ju, J. H., Lee, S., Park, D. A., Sung, Y., et al. (2018) · Journal of Rheumatic Diseases · doi:10.4078/jrd.2018.25.4.263 · Cited by 21
Kenanidis, E. I., Potoupnis, M. E., Kakoulidis, P., Leonidou, A. O., Sakellariou, G. T., Sayegh, F. E., & Tsiridis, E. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1040387 · Cited by 21
“Both daily and weekly administration of RIS appeared to be effective [148-155].”
BackgroundSummary of the draft federal clinical guidelines for osteoporosis
Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Kanis, J. А., Pigarova, E. A., Rodionova, S. S., Toroptsova, N. V., Nikitinskaya, O. A., Skripnikova, I. A., Drapkina, O. M., et al. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12710 · Cited by 20
Bone densitometry, steroids and osteoporosis
Blake, G. M., & Fogelman, I. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200211000-00012 · Cited by 20
Suzuki, K., Tsuji, S., Fukushima, Y., Nakase, T., Hamada, M., Tomita, T., & Yoshikawa, H. (2012) · Modern Rheumatology · doi:10.1007/s10165-012-0678-x · Cited by 19
Osteoporose e erosões osseas focais na artrite reumatóide: da patogênese ao tratamento
Pereira, I. A., & Pereira, R. M. R. (2004) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042004000500006 · Cited by 19
Prevention and Treatment of Corticosteroid-Induced Osteoporosis
Iwamoto, J., Takeda, T., & Satō, Y. (2005) · Yonsei Medical Journal · doi:10.3349/ymj.2005.46.4.456 · Cited by 19
Risedronate: a new oral bisphosphonate
Umland, E. T., & Boyce, E. G. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80116-8 · Cited by 17
Prévention et traitement de l’ostéoporose cortisonique
Roux, C., & Orcel, P. (2003) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(03)00105-x · Cited by 17
Cheng, X., Li, D., & Cui, R. (2023) · Journal of Engineering Research · doi:10.1016/j.jer.2023.100151 · Cited by 14
Kusano, J., Tanaka, S., Matsuda, H., Hara, Y., Fujii, Y., Suzuki, S., Sekiyama, M., Ando, E., Sugiyama, K., & Hirano, T. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12747 · Cited by 14
Neves, C., Alves, M., Delgado, J. L., & Medina, J. L. (2008) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 13
Risedronate for the Prevention and Treatment of Corticosteroid-Induced Osteoporosis
Dougherty, J. A. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a114 · Cited by 12
Orcel, P., & Roux, C. (2001) · Revue du Rhumatisme · doi:10.1016/s1169-8330(01)00181-8 · Cited by 12
Nagashima, M., Takahashi, H., Shimane, K., Nagase, Y., & Wauke, K. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4063 · Cited by 11
“Likewise, the amino-bisphosphonate risedronate is reportedly effective as a treatment for decreased bone density and vertebral fracture in patients on corticosteroid therapy [9,10].”
BackgroundMel'nichenko, G. A., Belaya, Z. E., Rozhinskaya, L. Y., Grebennikova, T. A., Pigarova, E. A., Toroptsova, N. V., Nikitinskaya, O. A., Farba, L. Y., Tarbaeva, N. V., Chernova, T. O., et al. (2016) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2016328-36 · Cited by 10
Marco, E., Coll-Fernández, R., Marín, M., Coll-Fernández, R., Pascual, M. T., Resa, J., Muñoz, L., Romero, M., Burnham, P., & Ciria, M. (2016) · Rehabilitación · doi:10.1016/j.rh.2016.04.004 · Cited by 11
Robinson, D. E., Ali, M. S., Strauss, V. Y., Elhussein, L., Abrahamsen, B., Arden, N., Ben‐Shlomo, Y., Caskey, F. J., Cooper, C. C., Dedman, D., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25170 · Cited by 9
Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates
Ringe, J. D., & Farahmand, P. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0467-z · Cited by 9
“A double-blind, placebo-controlled, prevention study recruited 120 postmenopausal women with rheumatoid arthritis needing more than 6 months of corticosteroid treatment [ 37 ].”
BackgroundInfluentialBrance, M. L., Larroudé, M. S., Zamora, N. V., Bagur, A., Graf, C. E., Giacoia, E., Diehl, M., Somma, L. F., Schneeberger, E. E., Salerni, H. H., et al. (2023) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001951 · Cited by 8
Takei, T., Itabashi, M., Tsukada, M., Sugiura, H., Moriyama, T., Kojima, C., Shiohira, S., Shimizu, A., Karasawa, K., Amemiya, N., et al. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3707 · Cited by 8
“Corticosteroid therapy is used in the management of various inflammatory diseases such as asthma, rheumatoid arthritis, systemic lupus erythematosus, and Crohn’s disease (20-22).”
BackgroundYamasaki, S. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05266-7 · Cited by 7
Osteoporosis secundaria a fármacos
Sallés, M., & Gelman, S. M. (2009) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2009.09.002 · Cited by 7
“La teriparatida (1-34) PTH parece tener un papel beneficioso en la OP secundaria a GC.”
BackgroundBisphosphonates in the Treatment of Glucocorticoid-Induced Osteoporosis
Doga, M., Bonadonna, S., Burattin, A., Carpinteri, R., Manelli, F., & Giustina, A. (2002) · KARGER eBooks · doi:10.1159/000061082 · Cited by 7
Osteoporosis due to steroid therapy
Braun, J., & Sieper, J. (2001) · Der Orthopäde · doi:10.1007/s001320170076 · Cited by 6
Williams, D. J., Bennett, K., & Feely, J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02218.x · Cited by 6
Prise en charge de l’ostéoporose cortisonique
Orcel, P. (2006) · La Presse Médicale · doi:10.1016/s0755-4982(06)74853-9 · Cited by 6
Les bisphosphonates en dehors de l’ostéoporose
Orcel, P., & Beaudreuil, J. (2002) · Revue du Rhumatisme · doi:10.1016/s1169-8330(01)00246-0 · Cited by 5
Brance, M. L., Larroudé, M. S., Somma, L. F., Giacoia, E., Diehl, M., Galich, A. M., Stieben, L. A. R., Maher, M. C., Vega, M. D. L., Ringer, A., et al. (2022) · Reumatología Clínica · doi:10.1016/j.reuma.2022.10.002 · Cited by 4
Prophylaxis in dermatologic patients receiving immunosuppressive therapy
Rencic, A., Caeiro, J. P., Hernández, M. I., & Nousari, H. C. (2002) · Dermatologic Therapy · doi:10.1046/j.1529-8019.2002.01544.x · Cited by 4
Metadata
- Authors
- Eastell, R., Devogelaer, J.-P., Peel, N. F. A., Chines, A. A., Bax, D. E., Sacco-Gibson, N., Nagant de Deuxchaisnes, C., & Russell, R. G. G.
- Affiliations
- University of Sheffield (GB)
- Procter & Gamble (United States) (US)
- Venue
- Osteoporosis International
- Published
- 2000-05-01
- Volume
- 11
- Issue
- 4
- Pages
- 331-337
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2018601087
- Cited by
- 134
- References
- 21
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- risedronate, bone mineral density, bone loss prevention, rheumatoid arthritis, glucocorticoid-induced osteoporosis, postmenopausal women, bisphosphonates, prednisolone, lumbar spine, femoral neck, trochanter, treatment withdrawal
- MeSH terms
- Risedronic Acid, Administration, Oral, Aged, Arthritis, Rheumatoid, Calcium Channel Blockers, Double-Blind Method, Female, Glucocorticoids, Humans, Osteoporosis, Prednisolone, Etidronic Acid, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.